Inicio
Resultado de la búsqueda
7 búsqueda de la palabra clave 'Acromegaly'
Clasificado(s) por (Año de edición descendente) Refinar búsqueda Genera el flujo rss de la búsqueda
Enlace permanente de la investigación
Título : Clinical biology of the pituitary adenoma Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2022 Títulos uniformes : Endocrine Reviews Idioma : Inglés (eng) Palabras clave : pituitary adenoma acromegaly prolactinoma Cushing’s disease aggressive pituitary tumor hypothalamus Resumen : All endocrine glands are susceptible to neoplastic growth, yet the health consequences of these neoplasms differ between endocrine tissues. Pituitary neoplasms are highly prevalent and overwhelmingly benign, exhibiting a spectrum of diverse behaviors and impact on health. To understand the clinical biology of these common yet often innocuous neoplasms, we review pituitary physiology, and adenoma epidemiology, pathophysiology, behavior, and clinical consequences. The anterior pituitary develops in response to a range of complex brain signals integrating with intrinsic ectodermal cell transcriptional events that together determine gland growth, cell type differentiation, and hormonal production, in turn maintaining optimal endocrine health. Pituitary adenomas occur in ten percent of the population; however, the overwhelming majority remain harmless during life. Triggered by somatic or germline mutations, disease-causing adenomas manifest pathogenic mechanisms that disrupt intra-pituitary signaling to promote benign cell proliferation associated with chromosomal instability. Cellular senescence acts as a mechanistic buffer protecting against malignant transformation, an extremely rare event. It is estimated that fewer than one thousandth of all pituitary adenomas cause clinically significant disease. Adenomas variably and adversely affect morbidity and mortality depending on cell type, hormone secretory activity, and growth behavior. For most clinically apparent adenomas, multimodal therapy controlling hormone secretion and adenoma growth lead to improved quality of life and normalized mortality. The clinical biology of pituitary adenomas and particularly their benign nature stands in marked contrast to other tumors of the endocrine system such as thyroid and neuroendocrine tumors. Mención de responsabilidad : Shlomo Melmed, Ursula B Kaiser, M Beatriz Lopes, Jerome Bertherat, Luis V Syro, Gerald Raverot, Martin Reincke, Gudmundur Johannsson, Albert Beckers, Maria Fleseriu, Andrea Giustina, John A H Wass, Ken K Y Ho Referencia : Endocr Rev. 2022 Apr 8;bnac010. DOI (Digital Object Identifier) : 10.1210/endrev/bnac010 PMID : 35395078 Derechos de uso : CC BY-NC-ND En línea : https://academic.oup.com/edrv/advance-article/doi/10.1210/endrev/bnac010/6565598 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6028 Clinical biology of the pituitary adenoma [documento electrónico] / Luis Vicente Syro Moreno, . - 2022.
Obra : Endocrine Reviews
Idioma : Inglés (eng)
Palabras clave : pituitary adenoma acromegaly prolactinoma Cushing’s disease aggressive pituitary tumor hypothalamus Resumen : All endocrine glands are susceptible to neoplastic growth, yet the health consequences of these neoplasms differ between endocrine tissues. Pituitary neoplasms are highly prevalent and overwhelmingly benign, exhibiting a spectrum of diverse behaviors and impact on health. To understand the clinical biology of these common yet often innocuous neoplasms, we review pituitary physiology, and adenoma epidemiology, pathophysiology, behavior, and clinical consequences. The anterior pituitary develops in response to a range of complex brain signals integrating with intrinsic ectodermal cell transcriptional events that together determine gland growth, cell type differentiation, and hormonal production, in turn maintaining optimal endocrine health. Pituitary adenomas occur in ten percent of the population; however, the overwhelming majority remain harmless during life. Triggered by somatic or germline mutations, disease-causing adenomas manifest pathogenic mechanisms that disrupt intra-pituitary signaling to promote benign cell proliferation associated with chromosomal instability. Cellular senescence acts as a mechanistic buffer protecting against malignant transformation, an extremely rare event. It is estimated that fewer than one thousandth of all pituitary adenomas cause clinically significant disease. Adenomas variably and adversely affect morbidity and mortality depending on cell type, hormone secretory activity, and growth behavior. For most clinically apparent adenomas, multimodal therapy controlling hormone secretion and adenoma growth lead to improved quality of life and normalized mortality. The clinical biology of pituitary adenomas and particularly their benign nature stands in marked contrast to other tumors of the endocrine system such as thyroid and neuroendocrine tumors. Mención de responsabilidad : Shlomo Melmed, Ursula B Kaiser, M Beatriz Lopes, Jerome Bertherat, Luis V Syro, Gerald Raverot, Martin Reincke, Gudmundur Johannsson, Albert Beckers, Maria Fleseriu, Andrea Giustina, John A H Wass, Ken K Y Ho Referencia : Endocr Rev. 2022 Apr 8;bnac010. DOI (Digital Object Identifier) : 10.1210/endrev/bnac010 PMID : 35395078 Derechos de uso : CC BY-NC-ND En línea : https://academic.oup.com/edrv/advance-article/doi/10.1210/endrev/bnac010/6565598 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6028 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001869 AC-2022-034 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
AC-2022-034Adobe Acrobat PDFPituitary society guidance: pituitary disease management and patient care recommendations during the COVID‐19 pandemic—an international perspective / Luis Vicente Syro Moreno
Título : Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID‐19 pandemic—an international perspective Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2020 Títulos uniformes : Pituitary Idioma : Inglés (eng) Palabras clave : Acromegaly COVID-19 Cushing’s disease Pituitary disease and surgery Prolactinomas SARS-CoV-2 Resumen : Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the viral strain that has caused the coronavirus disease 2019 (COVID-19) pandemic, has presented healthcare systems around the world with an unprecedented challenge. In locations with significant rates of viral transmission, social distancing measures and enforced 'lockdowns' are the new 'norm' as governments try to prevent healthcare services from being overwhelmed. However, with these measures have come important challenges for the delivery of existing services for other diseases and conditions. The clinical care of patients with pituitary disorders typically involves a multidisciplinary team, working in concert to deliver timely, often complex, disease investigation and management, including pituitary surgery. COVID-19 has brought about major disruption to such services, limiting access to care and opportunities for testing (both laboratory and radiological), and dramatically reducing the ability to safely undertake transsphenoidal surgery. In the absence of clinical trials to guide management of patients with pituitary disease during the COVID-19 pandemic, herein the Professional Education Committee of the Pituitary Society proposes guidance for continued safe management and care of this population. Mención de responsabilidad : Maria Fleseriu, Michael Buchfelder, Justin S. Cetas, Pouneh K. Fazeli, Susana M. Mallea-Gil, Mark Gurnell, Ann McCormack, Maria M. Pineyro, Luis V. Syro, Nicholas A. Tritos & Hani J. Marcus Referencia : Pituitary. 2020 Aug;23(4):327-337. DOI (Digital Object Identifier) : 10.1007/s11102-020-01059-7 PMID : 32556793 Derechos de uso : CC BY En línea : https://link.springer.com/article/10.1007/s11102-020-01059-7 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5121 Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID‐19 pandemic—an international perspective [documento electrónico] / Luis Vicente Syro Moreno, . - 2020.
Obra : Pituitary
Idioma : Inglés (eng)
Palabras clave : Acromegaly COVID-19 Cushing’s disease Pituitary disease and surgery Prolactinomas SARS-CoV-2 Resumen : Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the viral strain that has caused the coronavirus disease 2019 (COVID-19) pandemic, has presented healthcare systems around the world with an unprecedented challenge. In locations with significant rates of viral transmission, social distancing measures and enforced 'lockdowns' are the new 'norm' as governments try to prevent healthcare services from being overwhelmed. However, with these measures have come important challenges for the delivery of existing services for other diseases and conditions. The clinical care of patients with pituitary disorders typically involves a multidisciplinary team, working in concert to deliver timely, often complex, disease investigation and management, including pituitary surgery. COVID-19 has brought about major disruption to such services, limiting access to care and opportunities for testing (both laboratory and radiological), and dramatically reducing the ability to safely undertake transsphenoidal surgery. In the absence of clinical trials to guide management of patients with pituitary disease during the COVID-19 pandemic, herein the Professional Education Committee of the Pituitary Society proposes guidance for continued safe management and care of this population. Mención de responsabilidad : Maria Fleseriu, Michael Buchfelder, Justin S. Cetas, Pouneh K. Fazeli, Susana M. Mallea-Gil, Mark Gurnell, Ann McCormack, Maria M. Pineyro, Luis V. Syro, Nicholas A. Tritos & Hani J. Marcus Referencia : Pituitary. 2020 Aug;23(4):327-337. DOI (Digital Object Identifier) : 10.1007/s11102-020-01059-7 PMID : 32556793 Derechos de uso : CC BY En línea : https://link.springer.com/article/10.1007/s11102-020-01059-7 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5121 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001380 AC-2020-057 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2020-057.pdfAdobe Acrobat PDF
Título : Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2017 Títulos uniformes : Pituitary Idioma : Inglés (eng) Palabras clave : Acromegaly classification diagnosis immunohistochemistry pathology pituitary neoplasms Resumen : Introduction: Histologic, immunohistochemical and electron microscopic studies have provided conclusive evidence that a marked diversity exists between tumors which secrete growth hormone (GH) in excess. GH cell hyperplasia can also be associated with acromegaly in patients with extrapituitary GH—releasing hormone secreting tumors or in familial pituitary tumor syndromes. Materials and methods: A literature search was performed for information regarding pathology, GH-producing tumors and acromegaly. Results: This review summarizes the current knowledge on the morphology of GH-producing and silent GH adenomas, as well as GH hyperplasia of the pituitary. Conclusion: The importance of morphologic classification and identification of different subgroups of patients with GH-producing adenomas and their impact on clinical management is discussed. Mención de responsabilidad : Luis V Syro, Fabio Rotondo, Carlos A Serna, Leon D Ortiz, Kalman Kovacs Referencia : Pituitary. 2017 Feb;20(1):84-92. DOI (Digital Object Identifier) : 10.1007/s11102-016-0748-8 PMID : 27586499 En línea : https://link.springer.com/article/10.1007%2Fs11102-016-0748-8 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4088 Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary [documento electrónico] / Luis Vicente Syro Moreno, . - 2017.
Obra : Pituitary
Idioma : Inglés (eng)
Palabras clave : Acromegaly classification diagnosis immunohistochemistry pathology pituitary neoplasms Resumen : Introduction: Histologic, immunohistochemical and electron microscopic studies have provided conclusive evidence that a marked diversity exists between tumors which secrete growth hormone (GH) in excess. GH cell hyperplasia can also be associated with acromegaly in patients with extrapituitary GH—releasing hormone secreting tumors or in familial pituitary tumor syndromes. Materials and methods: A literature search was performed for information regarding pathology, GH-producing tumors and acromegaly. Results: This review summarizes the current knowledge on the morphology of GH-producing and silent GH adenomas, as well as GH hyperplasia of the pituitary. Conclusion: The importance of morphologic classification and identification of different subgroups of patients with GH-producing adenomas and their impact on clinical management is discussed. Mención de responsabilidad : Luis V Syro, Fabio Rotondo, Carlos A Serna, Leon D Ortiz, Kalman Kovacs Referencia : Pituitary. 2017 Feb;20(1):84-92. DOI (Digital Object Identifier) : 10.1007/s11102-016-0748-8 PMID : 27586499 En línea : https://link.springer.com/article/10.1007%2Fs11102-016-0748-8 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4088 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000697 AC-2017-086 Archivo digital Producción Científica Artículos científicos Disponible
Título : Progress in the Diagnosis and Classification of Pituitary Adenomas Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2015 Títulos uniformes : Frontiers in Endocrinology Idioma : Inglés (eng) Palabras clave : Diagnosis genetics pathology acromegaly multiple endocrine neoplasia type 1 pituitary adenoma familial isolated carney complex Resumen : Pituitary adenomas are common neoplasms. Their classification is based upon size, invasion of adjacent structures, sporadic or familial cases, biochemical activity, clinical manifestations, morphological characteristics, response to treatment and recurrence. Although they are considered benign tumors, some of them are difficult to treat due to their tendency to recur despite standardized treatment. Functional tumors present other challenges for normalizing their biochemical activity. Novel approaches for early diagnosis, as well as different perspectives on classification, may help to identify subgroups of patients with similar characteristics, creating opportunities to match each patient with the best personalized treatment option. In this paper, we present the progress in the diagnosis and classification of different subgroups of patients with pituitary tumors that may be managed with specific considerations according to their tumor subtype. Mención de responsabilidad : Luis V Syro, Fabio Rotondo, Alex Ramirez, Antonio Di Ieva, Murat Aydin Sav, Lina M Restrepo, Carlos A Serna, Kalman Kovacs Referencia : Front Endocrinol (Lausanne). 2015 Jun 12;6:97. DOI (Digital Object Identifier) : 10.3389/fendo.2015.00097 PMID : 26124750 En línea : https://www.frontiersin.org/articles/10.3389/fendo.2015.00097/full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3893 Progress in the Diagnosis and Classification of Pituitary Adenomas [documento electrónico] / Luis Vicente Syro Moreno, . - 2015.
Obra : Frontiers in Endocrinology
Idioma : Inglés (eng)
Palabras clave : Diagnosis genetics pathology acromegaly multiple endocrine neoplasia type 1 pituitary adenoma familial isolated carney complex Resumen : Pituitary adenomas are common neoplasms. Their classification is based upon size, invasion of adjacent structures, sporadic or familial cases, biochemical activity, clinical manifestations, morphological characteristics, response to treatment and recurrence. Although they are considered benign tumors, some of them are difficult to treat due to their tendency to recur despite standardized treatment. Functional tumors present other challenges for normalizing their biochemical activity. Novel approaches for early diagnosis, as well as different perspectives on classification, may help to identify subgroups of patients with similar characteristics, creating opportunities to match each patient with the best personalized treatment option. In this paper, we present the progress in the diagnosis and classification of different subgroups of patients with pituitary tumors that may be managed with specific considerations according to their tumor subtype. Mención de responsabilidad : Luis V Syro, Fabio Rotondo, Alex Ramirez, Antonio Di Ieva, Murat Aydin Sav, Lina M Restrepo, Carlos A Serna, Kalman Kovacs Referencia : Front Endocrinol (Lausanne). 2015 Jun 12;6:97. DOI (Digital Object Identifier) : 10.3389/fendo.2015.00097 PMID : 26124750 En línea : https://www.frontiersin.org/articles/10.3389/fendo.2015.00097/full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3893 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000473 AC-2015-026 Archivo digital Producción Científica Artículos científicos Disponible
Título : Somatotroph pituitary adenoma with acromegaly and autosomal dominant polycystic kidney disease: SSTR5 polymorphism and PKD1 mutation Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, ; Esdras Martín Vásquez Mejía, Fecha de publicación : 2011 Títulos uniformes : Pituitary Idioma : Inglés (eng) Palabras clave : Pituitary adenoma acromegaly adult polycystic kidney disease somatostatin receptor 5 single nucleotide polymorphism Resumen : A 39 year old woman with autosomal dominant polycystic kidney disease (ADPKD) presented with acromegaly and a pituitary macroadenoma. There was a family history of this renal disorder. She had undergone surgery for pituitary adenoma 6 years prior. Physical examination disclosed bitemporal hemianopsia and elevation of both basal growth hormone (GH) 106 ng/mL (normal 0–5) and insulin-like growth factor (IGF-1) 811 ng/mL (normal 48–255) blood levels. A magnetic resonance imaging scan disclosed a 3.0 cm sellar and suprasellar mass with both optic chiasm compression and left cavernous sinus invasion. Pathologic, cytogenetic, molecular and in silico analysis was undertaken. Histologic, immunohistochemical and ultrastructural studies of the lesion disclosed a sparsely granulated somatotroph adenoma. Standard chromosome analysis on the blood sample showed no abnormality. Sequence analysis of the coding regions of PKD1 and PKD2 employing DNA from both peripheral leukocytes and the tumor revealed the most common PKD1 mutation, 5014_5015delAG. Analysis of the entire SSTR5 gene disclosed the variant c.142C>A (p.L48M, rs4988483) in the heterozygous state in both blood and tumor, while no pathogenic mutations were noted in the MEN1, AIP, p27Kip1 and SSTR2 genes. To our knowledge, this is the fourth reported case of a GH-producing pituitary adenoma associated with ADPKD, but the first subjected to extensive morphological, ultrastructural, cytogenetic and molecular studies. The physical proximity of the PKD1 and SSTR5 genes on chromosome 16 suggests a causal relationship between ADPKD and somatotroph adenoma. Mención de responsabilidad : Luis V Syro, Jamie L Sundsbak, Bernd W Scheithauer, Rodrigo A Toledo, Mauricio Camargo, Christina M Heyer, Tomoko Sekiya, Humberto Uribe, Jorge I Escobar, Martin Vasquez, Fabio Rotondo, Sergio P A Toledo, Kalman Kovacs, Eva Horvath, Dusica Babovic-Vuksanovic, Peter C Harris Referencia : Pituitary. 2012 Sep;15(3):342-9. DOI (Digital Object Identifier) : 10.1007/s11102-011-0325-0 PMID : 21744088 En línea : https://link.springer.com/article/10.1007%2Fs11102-011-0325-0 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3557 Somatotroph pituitary adenoma with acromegaly and autosomal dominant polycystic kidney disease: SSTR5 polymorphism and PKD1 mutation [documento electrónico] / Luis Vicente Syro Moreno, ; Esdras Martín Vásquez Mejía, . - 2011.
Obra : Pituitary
Idioma : Inglés (eng)
Palabras clave : Pituitary adenoma acromegaly adult polycystic kidney disease somatostatin receptor 5 single nucleotide polymorphism Resumen : A 39 year old woman with autosomal dominant polycystic kidney disease (ADPKD) presented with acromegaly and a pituitary macroadenoma. There was a family history of this renal disorder. She had undergone surgery for pituitary adenoma 6 years prior. Physical examination disclosed bitemporal hemianopsia and elevation of both basal growth hormone (GH) 106 ng/mL (normal 0–5) and insulin-like growth factor (IGF-1) 811 ng/mL (normal 48–255) blood levels. A magnetic resonance imaging scan disclosed a 3.0 cm sellar and suprasellar mass with both optic chiasm compression and left cavernous sinus invasion. Pathologic, cytogenetic, molecular and in silico analysis was undertaken. Histologic, immunohistochemical and ultrastructural studies of the lesion disclosed a sparsely granulated somatotroph adenoma. Standard chromosome analysis on the blood sample showed no abnormality. Sequence analysis of the coding regions of PKD1 and PKD2 employing DNA from both peripheral leukocytes and the tumor revealed the most common PKD1 mutation, 5014_5015delAG. Analysis of the entire SSTR5 gene disclosed the variant c.142C>A (p.L48M, rs4988483) in the heterozygous state in both blood and tumor, while no pathogenic mutations were noted in the MEN1, AIP, p27Kip1 and SSTR2 genes. To our knowledge, this is the fourth reported case of a GH-producing pituitary adenoma associated with ADPKD, but the first subjected to extensive morphological, ultrastructural, cytogenetic and molecular studies. The physical proximity of the PKD1 and SSTR5 genes on chromosome 16 suggests a causal relationship between ADPKD and somatotroph adenoma. Mención de responsabilidad : Luis V Syro, Jamie L Sundsbak, Bernd W Scheithauer, Rodrigo A Toledo, Mauricio Camargo, Christina M Heyer, Tomoko Sekiya, Humberto Uribe, Jorge I Escobar, Martin Vasquez, Fabio Rotondo, Sergio P A Toledo, Kalman Kovacs, Eva Horvath, Dusica Babovic-Vuksanovic, Peter C Harris Referencia : Pituitary. 2012 Sep;15(3):342-9. DOI (Digital Object Identifier) : 10.1007/s11102-011-0325-0 PMID : 21744088 En línea : https://link.springer.com/article/10.1007%2Fs11102-011-0325-0 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3557 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000126 AC-2011-011 Archivo digital Producción Científica Artículos científicos Disponible PermalinkPermalink
